US BioTek Laboratories Completes Merger With NutriPATH Pathology
March 3, 2026
US BioTek Laboratories completed its merger with Australian functional pathology provider NutriPATH Pathology. The combined platform expands global access to personalized, root-cause-focused healthcare testing, combining immunological/integrative diagnostics capabilities with NutriPATH’s gut health, nutrition, hormone, and metabolic marker testing expertise.
- Buyers
- US BioTek Laboratories
- Targets
- NutriPATH Pathology
- Industry
- Healthcare Services
- Location
- Victoria, Australia
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
US BioTek Laboratories Acquires RealTime Laboratories
March 19, 2024
Healthcare Services
US BioTek Laboratories, a Pike Street Capital portfolio company, has acquired Dallas-based RealTime Laboratories to expand its diagnostic testing capabilities, specifically mycotoxin and infectious disease testing. The deal broadens the combined organization’s services and geographic footprint while both labs continue operating at their respective locations.
-
SourceBio International plc Acquires LDPath Limited
March 29, 2022
Healthcare Services
SourceBio International plc has completed a strategic acquisition of LDPath Limited, a London-based digital pathology testing provider. The deal expands SourceBio's digital and AI-enabled pathology capabilities and creates a larger private provider of cellular and digital pathology services for the U.K. healthcare market.
-
LabGenomics USA LLC Acquires QDx Pathology
September 5, 2023
Healthcare Services
LabGenomics USA LLC, a subsidiary of South Korea–based LabGenomics Co., Ltd., has acquired QDx Pathology, a U.S. clinical and molecular pathology laboratory. The deal, signed in August 2023, is intended to accelerate LabGenomics' entry and expansion into the North American diagnostics market by combining QDx's lab services with LabGenomics' NGS-based molecular diagnostics capabilities.
-
NeoGenomics Acquires Pathline
April 7, 2025
Healthcare Services
NeoGenomics, Inc. (NASDAQ: NEO) has completed its acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified pathology laboratory headquartered in Ramsey, New Jersey. The deal strengthens NeoGenomics' commercial presence in the Northeast United States and expands its molecular and hematology-oncology testing capabilities and access to its oncology test menu.
-
Core One Labs Acquires New Path Laboratories
December 23, 2021
Food & Beverage
Core One Labs Inc. has completed the acquisition of all outstanding share capital of New Path Laboratories Inc., a British Columbia-based developer and manufacturer of natural health products and functional mushroom dietary supplements. The deal was paid in common shares of Core One and is intended to expand Core One's presence in the functional mushrooms market and add retail distribution channels to generate sales revenue.
-
Agilent Technologies to Acquire Biocare Medical for $950 Million
March 9, 2026
Healthcare Services
Agilent Technologies entered into a definitive agreement to acquire Biocare Medical, a global provider of clinical and research pathology solutions, in an all-cash transaction valued at $950 million. The deal is designed to expand Agilent’s pathology portfolio—especially immunohistochemistry—and is expected to close no later than Agilent’s fourth fiscal quarter of 2026.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.